RecruitingNCT06731621

Psilocybin for Treatment-Resistant Depression in Autism

This study is recruiting. It focuses on depression and currently lists participation information in Canada.

Depression, Autism spectrumOtherFrom 18 Years to 65 Years

Need help deciding?

Ask HopeStage to review this study with me

Study reference: NCT06731621. HopeStage can help you review the study, but cannot decide medical eligibility.

In plain English

Key information made simple

This study is looking at whether questionnaires and follow-up can help people with Treatment Resistant Depression or Autism Spectrum Disorder. Participants receive a study treatment and complete follow-up visits and assessments. Taking part may give some people access to questionnaires and follow-up, but direct benefit is not guaranteed.

What to expect

Your next step

The official record suggests a mix of remote and in-person participation through a lab, with sites including Centre for Addiction and Mental Health in Toronto. Participation appears to involve questionnaires, interviews, or regular check-ins about day-to-day experience. The main fit is usually being able to understand the study and consent, while common reasons not to take part include pregnancy or breastfeeding and active substance or alcohol problems that could affect the results. This is an early-stage study, which usually means a smaller group and a focus on learning how the approach behaves.

Before joining

Questions to ask before joining

What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?

Study clarity

Things to check before joining

Study start dateStarted: November 1, 2024

Time commitment: long follow-up or multiple visits
Study phase: Not available
Enrollment: Not available
Recruitment status: Recruiting
Sponsor: Centre for Addiction and Mental Health
Sponsor type: Hospital / academic medical center
Main activity: observational follow-up
Intervention: Not available
Source: Official registry link

Want help reviewing this study?

Public study data

Key study information

Official title: Psilocybin for Treatment-Resistant Depression in Autism
Condition: Depression, Autism spectrum
Study status: Recruiting
Sponsor / lead affiliation: Centre for Addiction and Mental Health
Location / country: Canada
Registry: ClinicalTrials.gov
External trial ID: NCT06731621

Why this study may matter

This study may matter because it adds public evidence around depression. HopeStage presents it as a starting point for understanding the study, checking the official source, and preparing questions with a care team.

In practice

For you

Taking part may help improve understanding of your condition.

It requires regular follow-up, often through questionnaires or interviews.

Mixes in-person and remote participation.

Official source

Registry reference

This page links back to the public source record so people can verify details directly with the registry and research team.

If you want the full study description, eligibility criteria, locations, and sponsor information in the original format, this is the place to check before taking the next step.

Official title: Psilocybin for Treatment-Resistant Depression in Autism
Source: ClinicalTrials.gov
Official registry link: Open official registry
External trial ID: NCT06731621

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is Psilocybin for Treatment-Resistant Depression in Autism?

This study is exploring observational follow-up for people with depression. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed.

Who is behind this study, and what type of sponsor is it?

This study is sponsored by Centre for Addiction and Mental Health, a hospital or academic medical center. The Centre for Addiction and Mental Health is a mental health hospital and research center. The sponsor is based in Canada. Sponsor website: https://www.camh.ca. You can verify the sponsor and study responsibility in the official registry record.

What does participation involve, what phase is it, and what should I ask about safety?

This study may involve observational follow-up, study visits, and assessments. The time commitment is long follow-up or multiple visits. The study phase is not available in HopeStage data. Check the official source record to see whether a phase is listed. Enrollment is not available in HopeStage data. HopeStage cannot say whether a study is safe or right for you. Before joining, ask the research team about possible risks, time commitment, visits, side effects, compensation, safety monitoring, and whether participation may affect your current care.

Where can I verify the study details?

Use the official source record linked on this page to check the full study description, recruitment status, eligibility criteria, locations, sponsor information, phase, enrollment, contact details, and any listed risks or requirements.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me